Cargando…
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827151/ https://www.ncbi.nlm.nih.gov/pubmed/35678031 http://dx.doi.org/10.3324/haematol.2022.281137 |
_version_ | 1784867012181229568 |
---|---|
author | Kayser, Sabine Martínez-Cuadrón, David Hanoun, Maher Stölzel, Friedrich Gil, Cristina Reinhardt, H. Christian Aguiar, Eliana Schäfer-Eckart, Kerstin Burgues, Juan Miguel Bergua Steffen, Björn Bernal, Teresa Krause, Stefan W. Riaza, Rosalía Schliemann, Christoph Cervera, Jose Kaufmann, Martin Torres-Miñana, Laura Hänel, Mathias Acuña-Cruz, Evelyn Jost, Edgar Algarra, Jesus Lorenzo Crysandt, Martina Fransecky, Lars Cornago-Navascues, Javier Kraus, Sabrina Martinez-Lopez, Joaquin Einsele, Hermann Niemann, Dirk Neubauer, Andreas Seggewiss-Bernhardt, Ruth Scholl, Sebastian Klein, Stefan A. Schmid, Christoph Schaich, Markus Schmidt-Hieber, Martin Zukunft, Sven Ho, Anthony D. Platzbecker, Uwe Baldus, Claudia D. Müller-Tidow, Carsten Thiede, Christian Bornhäuser, Martin Serve, Hubert Levis, Mark J. Montesinos, Pau Röllig, Christoph Schlenk, Richard F. |
author_facet | Kayser, Sabine Martínez-Cuadrón, David Hanoun, Maher Stölzel, Friedrich Gil, Cristina Reinhardt, H. Christian Aguiar, Eliana Schäfer-Eckart, Kerstin Burgues, Juan Miguel Bergua Steffen, Björn Bernal, Teresa Krause, Stefan W. Riaza, Rosalía Schliemann, Christoph Cervera, Jose Kaufmann, Martin Torres-Miñana, Laura Hänel, Mathias Acuña-Cruz, Evelyn Jost, Edgar Algarra, Jesus Lorenzo Crysandt, Martina Fransecky, Lars Cornago-Navascues, Javier Kraus, Sabrina Martinez-Lopez, Joaquin Einsele, Hermann Niemann, Dirk Neubauer, Andreas Seggewiss-Bernhardt, Ruth Scholl, Sebastian Klein, Stefan A. Schmid, Christoph Schaich, Markus Schmidt-Hieber, Martin Zukunft, Sven Ho, Anthony D. Platzbecker, Uwe Baldus, Claudia D. Müller-Tidow, Carsten Thiede, Christian Bornhäuser, Martin Serve, Hubert Levis, Mark J. Montesinos, Pau Röllig, Christoph Schlenk, Richard F. |
author_sort | Kayser, Sabine |
collection | PubMed |
description | We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients had double CEBPA mutations. Data on response to intensive anthracycline-based induction therapy were available for 119 patients. Complete remission was achieved in 67% (n=80) and the early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a complete remission rate of 89%. Allogeneic hematopoietic cell transplantation was performed in 40 (34%) patients, of whom 19 were transplanted in first complete remission. The median follow-up of the intensively treated cohort was 5.76 years (95% confidence interval [95% CI]: 2.99-7.61 years). The 5-year overall survival and relapse-free survival rates were 30% (95% CI: 22-41%) and 27% (95% CI: 18-41%), respectively. An Andersen-Gill regression model on overall survival revealed that favorable-risk according to the European LeukemiaNet classification (hazard ratio [HR]=0.34; P=0.006) and trisomy 4 as sole abnormality (HR=0.41; P=0.01) were favorable factors, whereas age with a difference of 10 years (HR=1.15; P=0.11), female gender (HR=0.74; P=0.20) and allogeneic hematopoietic cell transplantation (HR=0.64; P=0.14) did not have an significant impact. In our cohort, patients with trisomy 4 as their sole abnormality had a high complete remission rate and favorable clinical outcome. Allogeneic hematopoietic cell transplantation did not seem to improve overall survival. |
format | Online Article Text |
id | pubmed-9827151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-98271512023-01-20 Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Kayser, Sabine Martínez-Cuadrón, David Hanoun, Maher Stölzel, Friedrich Gil, Cristina Reinhardt, H. Christian Aguiar, Eliana Schäfer-Eckart, Kerstin Burgues, Juan Miguel Bergua Steffen, Björn Bernal, Teresa Krause, Stefan W. Riaza, Rosalía Schliemann, Christoph Cervera, Jose Kaufmann, Martin Torres-Miñana, Laura Hänel, Mathias Acuña-Cruz, Evelyn Jost, Edgar Algarra, Jesus Lorenzo Crysandt, Martina Fransecky, Lars Cornago-Navascues, Javier Kraus, Sabrina Martinez-Lopez, Joaquin Einsele, Hermann Niemann, Dirk Neubauer, Andreas Seggewiss-Bernhardt, Ruth Scholl, Sebastian Klein, Stefan A. Schmid, Christoph Schaich, Markus Schmidt-Hieber, Martin Zukunft, Sven Ho, Anthony D. Platzbecker, Uwe Baldus, Claudia D. Müller-Tidow, Carsten Thiede, Christian Bornhäuser, Martin Serve, Hubert Levis, Mark J. Montesinos, Pau Röllig, Christoph Schlenk, Richard F. Haematologica Article - Acute Myeloid Leukemia We retrospectively studied 125 patients with acute myeloid leukemia and trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients had double CEBPA mutations. Data on response to intensive anthracycline-based induction therapy were available for 119 patients. Complete remission was achieved in 67% (n=80) and the early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a complete remission rate of 89%. Allogeneic hematopoietic cell transplantation was performed in 40 (34%) patients, of whom 19 were transplanted in first complete remission. The median follow-up of the intensively treated cohort was 5.76 years (95% confidence interval [95% CI]: 2.99-7.61 years). The 5-year overall survival and relapse-free survival rates were 30% (95% CI: 22-41%) and 27% (95% CI: 18-41%), respectively. An Andersen-Gill regression model on overall survival revealed that favorable-risk according to the European LeukemiaNet classification (hazard ratio [HR]=0.34; P=0.006) and trisomy 4 as sole abnormality (HR=0.41; P=0.01) were favorable factors, whereas age with a difference of 10 years (HR=1.15; P=0.11), female gender (HR=0.74; P=0.20) and allogeneic hematopoietic cell transplantation (HR=0.64; P=0.14) did not have an significant impact. In our cohort, patients with trisomy 4 as their sole abnormality had a high complete remission rate and favorable clinical outcome. Allogeneic hematopoietic cell transplantation did not seem to improve overall survival. Fondazione Ferrata Storti 2022-06-09 /pmc/articles/PMC9827151/ /pubmed/35678031 http://dx.doi.org/10.3324/haematol.2022.281137 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article - Acute Myeloid Leukemia Kayser, Sabine Martínez-Cuadrón, David Hanoun, Maher Stölzel, Friedrich Gil, Cristina Reinhardt, H. Christian Aguiar, Eliana Schäfer-Eckart, Kerstin Burgues, Juan Miguel Bergua Steffen, Björn Bernal, Teresa Krause, Stefan W. Riaza, Rosalía Schliemann, Christoph Cervera, Jose Kaufmann, Martin Torres-Miñana, Laura Hänel, Mathias Acuña-Cruz, Evelyn Jost, Edgar Algarra, Jesus Lorenzo Crysandt, Martina Fransecky, Lars Cornago-Navascues, Javier Kraus, Sabrina Martinez-Lopez, Joaquin Einsele, Hermann Niemann, Dirk Neubauer, Andreas Seggewiss-Bernhardt, Ruth Scholl, Sebastian Klein, Stefan A. Schmid, Christoph Schaich, Markus Schmidt-Hieber, Martin Zukunft, Sven Ho, Anthony D. Platzbecker, Uwe Baldus, Claudia D. Müller-Tidow, Carsten Thiede, Christian Bornhäuser, Martin Serve, Hubert Levis, Mark J. Montesinos, Pau Röllig, Christoph Schlenk, Richard F. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
title | Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
title_full | Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
title_fullStr | Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
title_full_unstemmed | Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
title_short | Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
title_sort | characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
topic | Article - Acute Myeloid Leukemia |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827151/ https://www.ncbi.nlm.nih.gov/pubmed/35678031 http://dx.doi.org/10.3324/haematol.2022.281137 |
work_keys_str_mv | AT kaysersabine characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT martinezcuadrondavid characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT hanounmaher characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT stolzelfriedrich characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT gilcristina characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT reinhardthchristian characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT aguiareliana characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schafereckartkerstin characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT burguesjuanmiguelbergua characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT steffenbjorn characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT bernalteresa characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT krausestefanw characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT riazarosalia characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schliemannchristoph characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT cerverajose characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT kaufmannmartin characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT torresminanalaura characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT hanelmathias characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT acunacruzevelyn characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT jostedgar characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT algarrajesuslorenzo characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT crysandtmartina characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT franseckylars characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT cornagonavascuesjavier characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT kraussabrina characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT martinezlopezjoaquin characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT einselehermann characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT niemanndirk characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT neubauerandreas characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT seggewissbernhardtruth characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schollsebastian characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT kleinstefana characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schmidchristoph characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schaichmarkus characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schmidthiebermartin characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT zukunftsven characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT hoanthonyd characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT platzbeckeruwe characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT baldusclaudiad characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT mullertidowcarsten characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT thiedechristian characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT bornhausermartin characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT servehubert characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT levismarkj characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT montesinospau characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT rolligchristoph characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 AT schlenkrichardf characteristicsandoutcomeofpatientswithacutemyeloidleukemiaandtrisomy4 |